Dentatorubral-Pallidoluysian Atrophy
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Dentatorubral-Pallidoluysian Atrophy

What is the definition of Dentatorubral-Pallidoluysian Atrophy?

Dentatorubral-pallidoluysian atrophy (DRPLA) is a progressive brain disorder that causes involuntary movements, mental and emotional problems, and a decline in thinking ability. The average age of onset for DRPLA is around 30 years, but this condition can appear any time between infancy and mid-adulthood.

What are the causes of Dentatorubral-Pallidoluysian Atrophy?

DRPLA is caused by a variant (also called mutation) in the ATN1 gene. This gene provides instructions for making a protein called atrophin 1. Although the exact function of atrophin 1 is unknown, it appears to play an important role in nerve cells (neurons) in many areas of the brain.

How prevalent is Dentatorubral-Pallidoluysian Atrophy?

DRPLA is most common in the Japanese population, where it is estimated to affect 2 to 7 per million people. However, this condition has also been seen in families around world.

Is Dentatorubral-Pallidoluysian Atrophy an inherited disorder?

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.  In most cases, an affected person has one parent with the condition.

Who are the top Dentatorubral-Pallidoluysian Atrophy Local Doctors?
Elite in Dentatorubral-Pallidoluysian Atrophy
Elite in Dentatorubral-Pallidoluysian Atrophy
Referral may be required
245 Burgundy St, 
Heidelberg, VIC, AU 

Samuel Berkovic practices practicing medicine in Heidelberg, Australia. Mr. Berkovic is rated as an Elite expert by MediFind in the treatment of Dentatorubral-Pallidoluysian Atrophy. He is also highly rated in 48 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Epilepsy, Partial Familial Epilepsy, and Epilepsy with Myoclonic-Atonic Seizures.

Elite in Dentatorubral-Pallidoluysian Atrophy
Elite in Dentatorubral-Pallidoluysian Atrophy
Referral may be required
Box 100, KYS, 
Kuopio, FI 

Reetta Kalviainen practices practicing medicine in Kuopio, Finland. Kalviainen is rated as an Elite expert by MediFind in the treatment of Dentatorubral-Pallidoluysian Atrophy. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Unverricht-Lundborg Syndrome, Dentatorubral-Pallidoluysian Atrophy, Lafora Disease, and Myoclonic Epilepsy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Dentatorubral-Pallidoluysian Atrophy
Elite in Dentatorubral-Pallidoluysian Atrophy
Referral may be required
Milan, IT 

Laura Canafoglia practices practicing medicine in Milan, Italy. Ms. Canafoglia is rated as an Elite expert by MediFind in the treatment of Dentatorubral-Pallidoluysian Atrophy. She is also highly rated in 28 other conditions, according to our data. Her clinical expertise encompasses Dentatorubral-Pallidoluysian Atrophy, Lafora Disease, Epilepsy with Myoclonic-Atonic Seizures, Myoclonic Epilepsy, and Gastrostomy.

What are the latest Dentatorubral-Pallidoluysian Atrophy Clinical Trials?
Global Mitochondrial Registry to Define Natural History and Outcome Measures to Achieve Definite Trial Readiness for Mitochondrial Disorders

Summary: The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)

Summary: The Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1) is focused on gathering longitudinal clinical data as well as biological samples (blood and/or urine) from male and female patients, of all ages, who have a molecular diagnosis of EPM1or CSTB-null-related disease. Currently, there are no therapies that halt disease progression in any CSTB-related diseases, high...

Who are the sources who wrote this article ?

Published Date: December 05, 2023
Published By: National Institutes of Health